These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 27400031)

  • 1. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.
    Okamoto Y; Fujita S; Morita H; Kizawa S; Ito T; Sakane K; Sohmiya K; Hoshiga M; Ishizaka N
    Heart Vessels; 2016 Jan; 31(1):66-73. PubMed ID: 25223536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
    Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
    Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.
    Seifert ME; de las Fuentes L; Ginsberg C; Rothstein M; Dietzen DJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
    Am J Nephrol; 2014; 39(5):392-9. PubMed ID: 24818573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.
    Shibata K; Fujita S; Morita H; Okamoto Y; Sohmiya K; Hoshiga M; Ishizaka N
    PLoS One; 2013; 8(9):e73184. PubMed ID: 24039882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
    Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
    Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
    Gan L; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 42(9):1058-1065. PubMed ID: 28989152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.
    Ozeki M; Fujita S; Kizawa S; Morita H; Sohmiya K; Hoshiga M; Ishizaka N
    BMC Nephrol; 2014 Sep; 15():147. PubMed ID: 25200959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
    Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
    J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender Specific Association between Serum Fibroblast Growth Factor 23/α-Klotho and Coronary Artery and Aortic Valve Calcification.
    Morita H; Takeda Y; Fujita S; Okamoto Y; Sakane K; Teramoto K; Ozeki M; Tasaki R; Kizawa S; Sohmiya K; Hoshiga M; Ishizaka N
    J Atheroscler Thromb; 2015; 22(12):1338-46. PubMed ID: 26279337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
    Liu QF; Ye JM; Yu LX; He AL; Sun Q; He DW; Li SS
    J Investig Med; 2018 Mar; 66(3):669-675. PubMed ID: 29061648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.